17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into an agreement to divest a selection of non-core products from the company’s portfolio sold in Latin America, 17 September 2021
Today, the European Commission is launching the European Health Emergency preparedness and Response Authority (HERA) to prevent, detect, and rapidly respond to health emergencies. 16 September 2021
The US regulator has granted approval for a first-in-class oral tyrosine kinase inhibitor (TKI) developed by Japanese pharma major Takeda Pharmaceutical. 16 September 2021
French privately-held pharma major Servier and Neurochlore have recently announced that, following a lack of efficacy in two Phase III trials of bumetanide for autism spectrum disorder (ASD) in adolescents, they would be terminating these trials early. 16 September 2021
Adding to the positive current data, US healthcare giant Johnson & Johnson today announced new results for its Ebola vaccine, which received European marketing authorization in July 2020. 15 September 2021
At the 2021 European Society of Cardiology (ESC) Congress, full results were presented for EMPEROR-Preserved, a Phase III trial investigating US pharma major Eli Lilly and family-owned German drugmaker Boehringer Ingelheim’s Jardiance (empagliflozin) in heart failure with preserved ejection fraction (HFpEF). 15 September 2021
USA-based Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients’ lives. 14 September 2021
New Jersey, USA-based precision medicine company Nuvectis Pharma has licensed exclusive worldwide rights to a novel small molecule being developed by the University of Edinburgh, in the UK. 14 September 2021
Binnopharm Group, a Russian pharmaceutical producer will invest more than 2.5 billion roubles ($33 million) in the development of new drugs within the next several years, according to the company which was launched in February this year. 14 September 2021
Ireland-headquartered fish oil-based heart drug specialist Amarin Corp has announced the first European launch of Vazkepa (icosapent ethyl) in Germany. 14 September 2021
UK endocrine diseases specialist Diurnal Group today announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the UK as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). 13 September 2021
British drug developer Nuformix (LSE: NFX) leapt 19.3% this morning, after it announced the signing of an exclusive global licensing agreement with fellow UK-based Oxilio, a privately held pharmaceutical development company, for NXP001 (a proprietary new form of aprepitant) for oncology indications. 13 September 2021
Prices for brand-name drugs in particular are higher in the USA compared with other high-income countries, most of which regulate drug prices. However, inconsistent availability of data on net prices (ie, prices after rebates and other discounts) complicates international comparisons of drug prices, according to new research. 13 September 2021
Sumitomo Dainippon Pharma has launched Twymeeg (imeglimin hydrochloride) in Japan, the first launch of the diabetes drug anywhere in the world. 10 September 2021
US Health and Human Services (HHS) Secretary Xavier Becerra yesterday unveiled a comprehensive plan to lower drug prices as part of a long-awaited report from the HHS to the White House that offers a wide-ranging series of recommendations on curbing rising drug costs 10 September 2021
Shares Ireland-incorporated Endo International rose almost 18% to $2.10 in after-hours trading yesterday, after the company announced a $50 million settlement to exit a New York opioid trial. 10 September 2021
Zambon, a privately-owned Italian pharmaceutical company, has presented positive final results from the Phase III PROMIS-I study at the European Respiratory Society (ERS) Annual Meeting. 9 September 2021
French privately-held pharma major Servier and Neurochlore have announced that no sign of effectiveness was observed in their two Phase III clinical studies assessing bumetanide versus placebo in the treatment of autism spectrum disorders (ASD) in children and adolescents. 9 September 2021
Swiss pharma giant Roche has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of German biotech TIB Molbiol Group. 9 September 2021
Positive high-level results have been released from the MANDALA and DENALI Phase III trials of PT027 (albuterol/budesonide), at both 180/160mcg and 180/80mcg doses, showing the meeting of all primary endpoints and demonstrating statistically-significant benefits in patients with asthma versus individual components albuterol, also known as salbutamol (180mcg) and budesonide (160mg). 9 September 2021
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.